Skip to main content

Table 2 Malaria and anaemia episodes and Mullen Scales of Early Learning (MSEL) scores by chemoprevention trial arm

From: Malaria illness mediated by anaemia lessens cognitive development in younger Ugandan children

  Malaria episodes before 2 years of age Malaria episodes 2–3 years of age Anaemia episodes before 2 years of age Anaemia episodes 2–3 years of age MSEL composite at 2 years of age MSEL composite at 3 years of age
RCT trial armHUU cohort
No chemoprevention (placebo) 8.68 (4.80) 7.70 (4.07) 7.95 (5.71) 0.48 (0.77) 76.08 (11.67) 75.15 (11.31)
Daily trimethoprim–sulfamethoxazole (TS) 7.25 (4.74)* 7.77 (3.82) 7.06 (5.37) 0.76 (0.95) 73.32 (12.78) 75.74 (13.74)
Monthly sulfadoxine–pyrimethamine (SP) 8.70 (4.85) 8.19 (4.08) 8.06 (5.48) 0.51 (0.69) 74.79 (11.46) 76.13 (11.03)
Monthly dihydroartemisinin–piperaquine (DP) 4.76 (4.39)*** 8.00 (3.83) 5.24 (4.41)** 0.49 (0.66) 75.78 (12.24) 77.04 (11.78)
RCT trial armHEU cohort
No chemoprevention (placebo) 6.87 (5.09) 6.94 (4.66) 6.36 (6.31) 0.70 (0.88) 73.00 (12.39) 74.06 (10.22)
Daily trimethoprim–sulfamethoxazole (TS) 2.59 (2.51)*** 6.21 (4.49) 4.83 (3.70) 0.76 (0.74) 75.56 (13.17) 74.21 (9.90)
Monthly sulfadoxine–pyrimethamine (SP) 5.85 (4.25) 6.27 (3.85) 7.42 (6.02) 0.65 (0.80) 74.45 (12.19) 70.73 (9.36)
Monthly dihydroartemisinin–piperaquine (DP) 2.74 (3.15)*** 5.68 (3.77) 4.88 (3.62) 0.68 (0.80) 74.45 (12.19) 69.21 (10.43)
  1. ** P < 0.01; *** P < 0.001